Booting Earth Optimization System
Thank you for your patience. Your civilization is very important to us.
Tisagenlecleucel (CAR T-cell Therapy)
Treatment for Acute lymphoid leukemia
Typical Dosage: 0.2 to 5 x 10^6 CAR-positive viable T cells/kg (for patients up to 50 kg) or 1 to 2.5 x 10^8 CAR-positive viable T cells (for patients over 50 kg)
Effectiveness
92%
Safety Score
25%
Clinical Trials
6
Participants
2K
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
25
DangerousModerateSafe
Treatment Details
Dosage Range
0.2 to 5 x 10^6 CAR-positive viable T cells/kg (for patients up to 50 kg) or 1 to 2.5 x 10^8 CAR-positive viable T cells (for patients over 50 kg)
Time to Effect
2-4 weeks
Treatment Duration
Single infusion, followed by long-term monitoring
Evidence Quality
MODERATEConfidence Score
90%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$475,000
Monitoring:$150,000
Side Effect Mgmt:$250,000
Total Annual:$875,000
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
POORICER
$600,000/QALY
QALYs Gained
3.5
Outcome-Based Costs
Cost per Responder
$1,067,073
Cost per Remission
$1,067,073
Comparison vs Salvage Chemotherapy
Cost Difference
+$750,000/year
More expensive
QALY Difference
+3.00 QALYs
Better outcomes
Dominance
No dominance
Tisagenlecleucel (CAR T-cell Therapy) Outcomes
for Acute lymphoid leukemia
Efficacy Outcomes
Overall Effectiveness
+92%
Response Rate
+82%
Remission Rate
+82%
Common Side Effects
Cytokine Release Syndrome (CRS)
+77%
Neurologic toxicities (ICANS)
+47%
B-cell aplasia
+90%
Infection
+43%
Fever
+85%
Sources:
WARNING: LIMITED TRIALS AVAILABLE
You can search for trials, but you probably can't join any because the 1% Treaty hasn't passed yet. Most trials are severely limited by lack of funding and bureaucratic barriers. Help change this!
Active Clinical Trials
2 active trials recruiting for Tisagenlecleucel (CAR T-cell Therapy) in Acute lymphoid leukemia
MT2017-45: CAR-T Cell Therapy for Heme Malignancies
NCT03642626ACTIVE NOT RECRUITINGPHASE2
150 participants
INTERVENTIONAL
Minneapolis, United States
Started: Dec 18, 2018
Study of Efficacy and Safety of Tisagenlecleucel in HR B-ALL EOC MRD Positive Patients
NCT03876769ACTIVE NOT RECRUITINGPHASE2
121 participants
INTERVENTIONAL
Birmingham, United States +44 more
Started: Jun 24, 2019
Completed Clinical Trials
1 completed trial for Tisagenlecleucel (CAR T-cell Therapy) in Acute lymphoid leukemia
CAR T Cells Real World Evidence Study Based on the French Hospital Claims Data Source (PMSI)
NCT05349201COMPLETED
273 participants
OBSERVATIONAL
East Hanover, United States
Started: Dec 9, 2020